Impact of Plasma Levels of Colistin in Patients With Carbapenem Resistant Acinetobacter Baumannii Infection

• Status: Completed
• Trial end date: 2018-04-04
• Target enrollment: 0
• Participant gender: All

Summary

This study purposed to examine the adequate range of therapeutic concentration for Korean people by observing curative effects, side effects, blood concentration, etc. in treating CRAB-infected patients with colistin.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: DongGuk University
• Treatments: Colistin

Criteria

Inclusion Criteria:

1. All adult patients (aged ≥18 years)

2. Microbiological evidence (sputum, urine, blood) of infection due to carbapenem-resistant Acinetobacter baumannii during hospitalization

3. Intravenous Colistimethate sodium treated patient with Acinetobacter baumannii infection who fulfill the above criteria

4. Patients who agree to the gathering clinical information by means of an informed consent

Exclusion Criteria:

1. Pregnancy and lactating women

2. Patients receiving Colistimethate sodium therapy for <48 hours

3. Patient of chronic renal disease defined as a Creatinine clearance <10 mL/min, Or requirement for peritoneal or hemo-dialysis or hemofiltration

4. Known hypersensitivity to Colistimethate sodium

5. Receiving intravenous colistin therapy within the past 30 days

6. Patients treated with nebulized Colistimethate sodium